4,4-二氟-环己烷甲醇 | 178312-48-6

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 中文名称: 4,4-二氟-环己烷甲醇
• 中文别名: (4,4-二氟环己基)甲醇
• 英文名称: (4,4-difluorocyclohexyl)methanol
• 英文别名: 4,4-difluorocyclohexane methanol
• CAS: 178312-48-6
• 化学式: C₇H₁₂F₂O
• 分子量: 150.168
• InChiKey: XJZNZSLOHZLFQP-UHFFFAOYSA-N

物化性质

• 密度：
  1.154 g/mL at 25 °C
• 闪点：
  101℃
• 沸点：
  207-213°C/760 mmHg

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品运输编号：
  NONH for all modes of transport
• 海关编码：
  2906199090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2-8°C，干燥密封。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4,4-Difluorocyclohexanemethanol
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 178312-48-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing vapours.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : 4,4-Difluorocyclohexane-1-methanol
(4,4-Difluorocyclohexyl)methanol
Formula : C7H12F2O
Molecular Weight : 150,17 g/mol
CAS-No. : 178312-48-6
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4,4-Difluorocyclohexanemethanol
Skin Irrit. 2; Eye Irrit. 2; STOT -
SE 3; H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4,4-Difluorocyclohexanemethanol
Xi, R36/37/38 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
no data available
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Impervious clothing., The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 207 - 213 °C
boiling range
g) Flash point 101 °C
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,1543 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Inhalation: no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Eye Irrit. Eye irritation
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Skin Irrit. Skin irritation
STOT SE Specific target organ toxicity - single exposure
Full text of R-phrases referred to under sections 2 and 3
Xi Irritant
R36/37/38 Irritating to eyes, respiratory system and skin.
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

简介

4,4-二氟环己基)甲醇是一种有机中间体，可通过四氢铝锂与4,4-二氟环己烷甲酸乙酯反应制备得到。

制备

在氮气氛围中，将10克（52.03毫米摩尔）的4,4-二氟环己烷甲酸乙酯溶解于100毫升四氢呋喃（THF）中，并冷却至1摄氏度。缓慢滴加五十五点二三毫摩尔的四氢铝锂，保持反应温度低于10摄氏度。待溶液达到20摄氏度后，在此温度下搅拌约1小时。随后将反应混合物冷却至10摄氏度，并通过连续且缓慢地加入2.2毫升水、2.2毫升15重量/体积百分比的氢氧化钠水溶液和6.6毫升水来小心淬灭。在20摄氏度下搅拌30分钟后，过滤除去固体并用THF洗涤。使用硫酸镁干燥反应液，再通过真空蒸发得到粗品（4,4-二氟环己基）甲醇，产率为92%。

反应信息

• 作为反应物：
  描述：

  4,4-二氟-环己烷甲醇 在 (2S)-2-[二苯基[(三甲基硅酯)氧基]甲基]-吡咯烷 、 盐酸 、 草酰氯 、 二甲基亚砜 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 188.5h， 生成 (1R,2S,3R,5S)-1-hydroxy-6-(4-methoxybenzyl)-3-phenyl-2-(1-phenylethyl)-8-oxa-6-azabicyclo[3.2.1]octan-7-one
  参考文献：
  名称：

  通过有机催化和超强酸活化合成对映体富集的亚甲基桥连苯并恶唑。

  摘要：

  以直接的方式实现与生物活性天然产物有关的对映体富集的精细三维分子的合成仍然是有机合成中的长期追求。对映选择性有机催化潜在地提供了解决这一问题的独特机会，特别是当与互补的活化方式结合使用时。在这里，我们报告简单线性非手性容易获得的前体的有机催化和超强酸活化的顺序关联，以促进表现出三到五个完全受控的立体中心的独特的高度精细的手性亚甲基桥联的苯并氮烷的形成。这种奇特的骨架很难通过标准的合成方法组装，与具有生物活性的天然和合成吗啡喃和苯并吗啡紧密相关。

  DOI：

  10.1002/anie.201912043
• 作为产物：
  描述：

  对环己酮甲酸乙酯 在 二乙胺基三氟化硫 、 间氯过氧苯甲酸 、 lithium aluminium tetrahydride 作用下， 以 二氯甲烷 、 水 、 四氢呋喃 为溶剂， 反应 44.0h， 以62%的产率得到4,4-二氟-环己烷甲醇
  参考文献：
  名称：

  [EN] FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE
  [FR] COMPOSÉS DE FLUORO-PERHEXILINE ET LEUR UTILISATION THÉRAPEUTIQUE

  摘要：

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及以下式（在本文中也称为FPER化合物）的某些氟代perhexiline化合物，例如用于治疗包括已知可用perhexiline治疗或已知可用perhexiline治疗的紊乱（例如疾病），包括通过抑制肉碱棕榈酰基转移酶（CPT）改善的紊乱，如：心绞痛；心力衰竭（HF）；缺血性心脏病（IHD）；心肌病；心脏心律失常；心脏瓣膜狭窄；肥厚型心肌病（HCM）；冠心病；以及其他疾病，例如糖尿病和癌症。本发明还涉及包括这些化合物的药物组合物，以及这些化合物和组合物的用途，例如在治疗中的用途。

  公开号：

  WO2014184561A1

文献信息

• [EN] NITRILE COMPOUND AND ITS USE IN PEST CONTROL<br/>[FR] COMPOSE NITRILE ET SON UTILISATION POUR LE CONTROLE DES INSECTES ET ANIMAUX NUISIBLES
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2005063694A1

  公开（公告）日：2005-07-14

  The present invention provides a nitrile compound represented by the formula (I): wherein R represents C1-C4 fluoroalkyl, Q represents halogen, C1-C11 alkyl optionally substituted with halogen, C2-C6 alkenyl group optionally substituted with halogen, C2-C6 alkynyl optionally substituted with halogen, C3-C7 cycloalkyl optionally substituted with halogen or (C3-C7 cycloalkyl optionally substituted with halogen)C1-C4 alkyl, which has excellent control effect against pests.

  本发明提供了一种由式(I)表示的腈化合物：其中R代表C1-C4氟烷基，Q代表卤素，C1-C11烷基可选择地取代卤素，C2-C6烯基基团可选择地取代卤素，C2-C6炔基可选择地取代卤素，C3-C7环烷基可选择地取代卤素或(C3-C7环烷基可选择地取代卤素)C1-C4烷基，对害虫具有出色的控制效果。
• [EN] INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DE NOROVIRUS ET DE CORONAVIRUS
  申请人：COCRYSTAL PHARMA INC

  公开号：WO2021206876A1

  公开（公告）日：2021-10-14

  Compounds of Formula (I) and methods of inhibiting the replication of viruses in a biological sample or patient, of reducing the amount of viruses in a biological sample or patient, and of treating a virus infection in a patient, comprising administering to said biological sample or patient an effective amount of a compound represented by Formula (I), a compound of Table A or B or a pharmaceutically acceptable salt thereof.

  公式（I）化合物及抑制生物样本或患者中病毒复制、减少生物样本或患者中病毒数量、以及治疗患者病毒感染的方法，包括向所述生物样本或患者投与由公式（I）表示的化合物、表A或B中的化合物或其药用可接受盐的有效量。
• Solid dispersions containing an apoptosis-inducing agent
  申请人：AbbVie Inc.

  公开号：US10213433B2

  公开（公告）日：2019-02-26

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  一种促凋亡的固体分散体包括本文所定义的具有本文所述的化学式I的Bcl-2家族蛋白抑制化合物，以基本非晶态形式分散在包括（a）药学上可接受的水溶性聚合物载体和（b）药学上可接受的表面活性剂的固体基质中。制备这种固体分散体的方法包括在合适的溶剂中溶解化合物、聚合物载体和表面活性剂，并去除溶剂以提供包括聚合物载体和表面活性剂并在其中以基本非晶态形式分散有化合物的固体基质。这种固体分散体适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达所特征的疾病的受试者，例如癌症。
• 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
  申请人：Saito Daisuke Roland

  公开号：US20090062333A1

  公开（公告）日：2009-03-05

  The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R 2 , R 7 , and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  本发明提供了式(I)的8-氮杂双环[3.2.1]辛基-2-羟基苯甲酰胺化合物： 式中，R2、R7和m如说明书中所定义，或其药用可接受的盐，这些化合物是μ阿片受体的拮抗剂。本发明还提供了包含这些化合物的药物组合物，使用这些化合物治疗与μ阿片受体活性相关病症的方法，以及用于制备这些化合物的过程和中间体。
• Hexafluoroisopropyl Sulfamate: A Useful Reagent for the Synthesis of Sulfamates and Sulfamides
  作者：Matthew A. Sguazzin、Jarrod W. Johnson、Jakob Magolan

  DOI：10.1021/acs.orglett.1c00855

  日期：2021.5.7

  Sulfamates and sulfamides are most often synthesized from alcohols and amines with sulfamoyl chloride, which is an unstable reagent. We have identified hexafluoroisopropyl sulfamate (HFIPS) as a bench-stable solid that reacts readily with a wide variety of alcohols, amines, phenols, and anilines under mild reaction conditions. The sole byproduct of the reaction is hexafluoroisopropanol (HFIP) and reaction

  氨基磺酸盐和磺酰胺最经常是由醇和胺与氨磺酰氯合成的，氨磺酰氯是不稳定的试剂。我们已经确定六氟异丙基氨基磺酸盐（HFIPS）是一种稳定的固体，在温和的反应条件下，它很容易与多种醇，胺，酚和苯胺反应。反应的唯一副产物是六氟异丙醇（HFIP），在进行水后处理（可选）并通过蒸发除去溶剂后，通常可以高纯度分离反应产物。